Cagrilintide
Cagrilintide is available as a standalone catalog topic and also appears in a separate combination with semaglutide. Listed specification: 5 mg.
Find a topic, choose a reference, and explore the context.
122 references
Cagrilintide is available as a standalone catalog topic and also appears in a separate combination with semaglutide. Listed specification: 5 mg.
Cagrilintide is available as a standalone catalog topic and also appears in a separate combination with semaglutide. Listed specification: 10 mg.
This listing combines cagrilintide and semaglutide under a 10 mg blend specification. Listed specification: 10 mg.
Cartalax is a 20 mg reference in the named-compound directory, separate from similarly sized short-peptide products. Listed specification: 20 mg.
The directory lists Cerebrolysin in a 60 mg reference format. The name and unit presentation deserve careful checking against actual product documentation. Listed specification: 60 mg.
Chonluten has a dedicated 20 mg catalog entry. It is kept distinct from Cartalax and other products with the same nominal size. Listed specification: 20 mg.
CJC-1295 and GHRP-2 are grouped in a 10 mg blend entry, separate from the CJC-1295/ipamorelin combinations. Listed specification: 10 mg.
CJC-1295 DAC is listed separately from the no-DAC form, with 2 mg and 5 mg reference sizes. Listed specification: 2 mg.
CJC-1295 DAC is listed separately from the no-DAC form, with 2 mg and 5 mg reference sizes. Listed specification: 5 mg.
This stack pairs separately listed CJC-1295 DAC and ipamorelin vials, with two CJC-1295 size options. Listed specification: 2 mg + 5 mg separate vials.
This stack pairs separately listed CJC-1295 DAC and ipamorelin vials, with two CJC-1295 size options. Listed specification: 5 mg + 5 mg separate vials.
CJC-1295 NO DAC has a standalone 5 mg listing and appears in an independently listed combination with ipamorelin. Listed specification: 5 mg.